and oncogenes such as RAS to multiple essential cellular functions. The PI3K pathway is tightly controlled by a class of PI3Ks that generate the lipid second messenger phosphatidylinositol-3,4,5 ...

Gupta et al. now use mouse models of Ras-mediated tumorigenesis and validate the importance of the phosphatidylinositol 3-kinase (PI3K) pathway in Ras-induced tumorigenesis. Most of the studies ...

VVD-159642, Vividion’s fourth clinical-stage program stemming from its chemoproteomics discovery platform, is designed to improve patient outcomes by inhibiting RAS-PI3Kα, a key signaling ...

A second drug candidate, BBO-10203, blocks the interaction between RAS and PI3K alpha, a family of enzymes involved in cellular growth and proliferation. While PI3K alpha inhibitors have reached ...

This figure illustrates the major signaling pathways and their intricate crosstalk in BC, focusing on the GPCR, RTKs, RAS/RAF/MEK1/2/ERK1/2, MAPK, HER2, PI3K/Akt/mTOR, Wnt/β-catenin, NF-κB ...

The laboratory is studying small molecules that selectively inhibit the components of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. These compounds are being used as reagents to define the role of these ...

The authors discuss several major pathways involved in breast cancer, including PI3K/Akt/mTOR, RAS/RAF/MEK/ERK, HER2, Wnt/β-catenin, Notch, NF-κB, and the DNA damage response (DDR). These ...

BBO-10203 is an orally bioavailable small molecule with a novel mechanism of action that is designed to inhibit the physical interaction between RAS and PI3Kα, resulting in the inhibition of RAS ...

Mutations in the oncogene KRAS are widespread in several human cancers, including pancreatic ductal adenocarcinomas (92%), colorectal carcinomas (49%) and lung adenocarcinomas (35%). These mutations ...